Ipilimumab (Yervoy®, MDX010), an anti-CTLA-4 monoclonal antibody, was developed by the Medarex company in 1999 and has achieved remarkable results in numerous clinical studies into the treatment of patients with advanced melanoma [72–76]. Here, CTLA4 is linked to melanoma.